OncoMatch/Clinical Trials/NCT05572229
Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma
Is NCT05572229 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Teclistamab and Daratumumab for multiple myeloma.
Treatment: Teclistamab · Daratumumab · Lenalidomide — The primary hypothesis of this study is that teclistamab SC in combination with daratumumab SC or lenalidomide will be safe and induce a high rate of VGPR or better in newly diagnosed multiple myeloma patients This is an open-label, multicenter, non-comparative, 2-cohort, 2-stage with interruption of enrollment for an efficacy and safety interim analysis, interventional Phase 2 study evaluating the efficacy and safety of a combination with Tec-Dara (Cohort A) or Tec-Len (Cohort B) in patients with newly diagnosed multiple myeloma who are not eligible for SCT.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Endocrine / hormonal
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: any therapy for multiple myeloma or smoldering myeloma
Exception: short course of corticosteroids prior to signing ICF (not to exceed 40 mg of dexamethasone, or equivalent per day for a maximum of 4 days, total of 160 mg dexamethasone or equivalent)
Any prior therapy for multiple myeloma or smoldering myeloma other than a short course of corticosteroids prior to signing ICF (not to exceed 40 mg of dexamethasone, or equivalent per day for a maximum of 4 days, total of 160 mg dexamethasone or equivalent).
Cannot have received: radiotherapy
Radiotherapy within 14 days or focal radiation within 7 days.
Cannot have received: corticosteroids
Exception: pretreatment medications excluded
Received a cumulative dose of corticosteroids equivalent to ≥140 mg of prednisone within 14-days before the first dose of study drug (does not include pretreatment medications).
Cannot have received: live, attenuated vaccine
Exception: Non-live or non-replicating vaccines authorized for emergency use (eg, COVID-19) are allowed.
Received a live, attenuated vaccine within 4 weeks before the first dose of study drug. Non-live or non-replicating vaccines authorized for emergency use (eg, COVID-19) are allowed.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05572229 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages